Krakowskie Centrum Medyczne Sp. z o.o.

The Krakowskie Centrum Medyczne is evaluating new lipid‑lowering strategies and combination treatments to lower the risk of heart attack, stroke, and cardiovascular death.

• atherosclerotic cardiovascular disease in primary prevention
• Patients at high risk without prior myocardial infarction or stroke
• Coronary plaque reduction with obicetrapib/ezetimibe
• Inclisiran for major adverse cardiovascular events
• Evolocumab to prevent coronary events

The goal is to improve long‑term heart health through novel therapies and better risk management.

Research focuses on inflammatory bowel conditions and celiac disease, testing agents that target gut inflammation and immune response.

• Moderately to severely active Crohn’s disease
• Ulcerative colitis clinical activity
• Non‑responsive celiac disease (NRCD)
• Oral NX‑13 for ulcerative colitis
• Tulisokibart in Crohn’s disease

These studies aim to provide new treatment options that reduce symptoms and improve intestinal healing.

Trials explore therapies that modulate immune pathways in autoimmune disorders such as lupus, Sjögren’s syndrome, and systemic diseases.

• systemic lupus erythematosus activity reduction
• Moderate‑to‑severe Sjögren’s syndrome systemic manifestations
• Obexelimab for lupus disease activity
• Dazodalibep targeting Sjögren’s systemic disease
• Immune modulation with TransCon IL‑2 β/γ in cancer‑related immune contexts

The purpose is to assess safety and effectiveness of emerging immunotherapies for chronic autoimmune conditions.

Studies address joint degeneration and bone health, evaluating agents that may slow disease progression and improve function.

• knee osteoarthritis pain and structural outcomes
• Postmenopausal osteoporosis bone mineral density
• Active psoriatic arthritis treatment efficacy
• Musculoskeletal and neural physiological phenomena in disease
• Obesity‑related musculoskeletal impact

These trials seek to enhance mobility and reduce fracture risk through innovative therapies.

The site is conducting oncology studies that test novel agents and combinations in solid tumors and melanoma, focusing on safety and tumor response.

• Locally advanced or metastatic solid tumor malignancies
• Adjuvant treatment for Stage IIB‑III melanoma
• Post‑anti‑PD‑1 melanoma therapy
• Second‑line HER2‑positive breast cancer
• Platinum‑resistant ovarian cancer

The objective is to identify effective cancer therapies that improve survival and quality of life.

Research includes metabolic disorders such as hypertriglyceridemia, non‑alcoholic steatohepatitis, and obesity, testing agents that modify lipid metabolism and weight.

• Severe hypertriglyceridemia reduction
• Non‑alcoholic steatohepatitis (NASH) fibrosis improvement
• Obesity and overweight management
• Metabolism modulation with pegozafermin
• Orforglipron for BMI reduction

These studies aim to lower cardiovascular risk and improve metabolic health.

Clinical trials target chronic lung conditions and viral infections, evaluating inhaled therapies and vaccines to reduce exacerbations and infections.

• chronic obstructive pulmonary disease (COPD) triple therapy outcomes
• Respiratory syncytial virus (RSV) vaccine efficacy in older adults
• Influenza virus vaccine (Fluad) immunogenicity
• Human metapneumovirus (hMPV) prevention
• Respiratory outcomes in severe COPD

The purpose is to enhance lung function and protect vulnerable populations from respiratory pathogens.

Investigations focus on inflammatory skin disorders, assessing targeted inhibitors and immunotherapies for plaque psoriasis, vitiligo, and related conditions.

• Moderate‑to‑severe plaque psoriasis long‑term safety
• Ritlecitinib for nonsegmental vitiligo
• Deucravacitinib in active psoriatic arthritis
• Skin‑related immune system phenomena
• Therapies for severe atopic dermatitis (not listed but implied)

These trials seek to offer new options for patients with chronic skin inflammation and pigment disorders.

The centre evaluates antiviral vaccines and treatments for influenza, RSV, and other respiratory viruses, aiming to reduce infection rates in high‑risk groups.

• influenza virus vaccine (Fluad) comparative study
• RSV and hMPV VLP vaccine safety and efficacy
• RSVPreF3 OA revaccination immune response
• RSV vaccine humoral response in Chinese older adults
• Viral disease prevention in adults ≥60 years

The goal is to develop effective immunizations that protect elderly populations from severe viral illness.

Studies explore underlying immune mechanisms, including cytokine signaling and cellular responses, to support therapeutic development across diseases.

• Immune system phenomena in Sjögren’s syndrome
• Immune modulation with TransCon IL‑2 β/γ
• Phenotypic analysis of T‑cell activation in cancer trials
• Immune system processes targeted by novel biologics
• Biomarker evaluation in autoimmune studies

These investigations aim to clarify how immune pathways can be harnessed for treatment.

Clinical work examines therapeutic impact on immune signaling, focusing on cytokine inhibition and checkpoint modulation.

• Checkpoint inhibitor combinations with TransCon IL‑2 β/γ
• Deucravacitinib inhibition of TYK2 in psoriatic arthritis
• Ritlecitinib JAK inhibition in vitiligo
• IL‑2 β/γ pathway activation in solid tumor trials
• Immune process targeting in systemic lupus erythematosus

The purpose is to assess safety and efficacy of agents that fine‑tune immune activity.

Research includes metabolic regulation in liver disease and lipid disorders, testing agents that influence triglyceride and cholesterol pathways.

• PeGOZAFERMIN effect on fasting serum triglycerides
• Plozasiran lowering triglyceride levels
• Metabolic impact of elafibranor in primary biliary cholangitis
• Metabolism of lipid‑lowering agents in cardiovascular trials
• Metabolic outcomes in NASH fibrosis studies

These studies aim to improve metabolic health and reduce disease progression.

The site investigates physiological processes affecting joints, bones, and neural pathways, supporting therapies for arthritis and osteoporosis.

• Joint structural changes in knee osteoarthritis with LNA043
• Bone mineral density response to biosimilar LY06006
• Neural involvement in chronic pain of osteoarthritis
• Musculoskeletal physiology in obesity‑related joint stress
• Biomarker assessment of bone turnover in postmenopausal women

The aim is to validate treatments that preserve joint integrity and bone strength.